Abstract
The history of HIV treatment is characterised by a rapid development. In 1987, 6 years after the discovery of AIDS, the US Food and Drug administration approved the first drug against HIV. Since then three different classes of antiretroviral drugs including 16 drugs are currently available, others have reached phase III studies and immunotherapy and vaccines are in development.
Keywords
- Human Immunodeficiency Virus
- Human Immunodeficiency Virus Type
- Human Immunodeficiency Virus Infection
- Triple Therapy
- Human Immunodeficiency Virus Protease
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT et al. (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.N Engl J Med 317: 185–191
Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS et al. (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.N Engl J Med 317: 192–197
Fischl MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, Antoniskis D, Ho M, Richman DD, Fuchs E et al. (1990) A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.N Engl J Med 323: 1009–1014
Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD et al. (1990) The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.Ann Intern Med 112: 727–737
Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH Jr, Reichman RC, Bartlett JA, Hirsch MS et al. (1990) Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.N Engl J Med 322: 941–949
Concorde Coordinating Committee (1994) Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection.Lancet 343: 871–881
Larder BA, Kellam P, Kemp SD (1991) Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.AIDS 5: 137–144
Fitzgibbon JE, Howell RM, Schwartzer TA, Gocke DJ, Dubin DT (1991) Invivo prevalence of azidothymidine (AZT) resistance mutations in an AIDS patient before and after AZT therapy.AIDS Res Hum Retroviruses 7: 265–269
Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G et al. (1992) A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.N Engl J Med 327: 581–587
Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA 3rd, Gupta P, Rasheed S, Coombs R et al. (1994) Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.J Infect Dis 169: 722–729
Moyle G (2000) Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?Drug Saf 23: 467–481
Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG et al. (1993) Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.Ann Intern Med 119: 786–793
Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC, Powderly WG (1995) Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The MAID AIDS Clinical Trials Group.Ann Intern Med 122: 24–32
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M et al. (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.N Engl J Med 335: 1081–1090
Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A et al. (1996) The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.N Engl J Med 335: 1091–1098
Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, D’Aquila RT et al. (1998) Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200–500 CD4 cells/n[11113(ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.J Infect Dis 177: 617–624
Delta Coordinating Committee (1996) Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in infected individuals. individuals.Lancet 348: 283–291
Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M (1995) Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.N Engl J Med 333: 1662–1669
Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H (1996) Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naïve patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.JAMA 276: 118–125
Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhoj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L et al. (1996) Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.JAMA 276: 111–117
Molina JM, Chêne G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T et al. (1999) The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.J Infect Dis 180: 351–358
Kuritzkes DR, Marchner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME et al. (1999) Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial.AIDS 13: 685–694
Danner SA, Can A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V et al. (1995) A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.N Engl J Med 333: 1528–1533
Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM et al. (1995) A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.N Engl J Med 333: 1534–1539
Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, Burger HU, Bragman K, Pinching AJ, Weber JN (1995) Safety and activity of saquinavir in HIV infection.Lancet 345: 952–955
Steigbigel R, Berry P, Teppler H et al. (1996) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.I1 th International Conference on AIDS 7–12 July 1996, Vancouver, BC, Canada, Abstract Mo.B.412
Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyayskiy T, Niu P, Lyons N et al. (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.Nat Med 2: 760–766
Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ et al. (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.N Engl J Med; 334: 1011–1017
Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.N Engl J Med 337: 734–739
Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.Ann Intern Med 126: 946–954
Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.N Engl J Med 338: 853–860
Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R et al. (1997) Reductions in viral load and increases in T lymphocyte numbers in treatment-naïve patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.Antiviral Ther 2: 175–183
Can A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, Cooper DA (2000) A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombol study.AIDS 14: 1171–1180
Clendeninn N, Quart B, Anderson R, Knowles M, ChangY (1988) Analysis of long-term virologic data from the Viracept®(Nelfinavir, NFV) 511 protocol using 3 HIV-RNA assays.5th Conference on Retroviruses and Opportunistic Infections 1–5 February 1998, Chicago, Illinois, USA, Abstract 372
Bart PA, Gizzard GP, Gallant S, Welbon C, Graziosi C, Chave JP, Meylan P, Martin G, Steel H, Spreen W et al. (1998) Combination abacavir/amprenavir therapy in HIV-1-infected antiretroviral-naïve subjects with CD4+ counts >400 cells/RI and viral load >5,000 copies/ml.5th Conference on Retroviruses and Opportunistic Infections 1–5 February 1998, Chicago, Illinois, USA, Abstract 365
Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H et al. (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.Lancet 353: 863–868
Lucas GM, Chaisson RE, Moore RD (1999) Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.Ann Intern Med 131: 81–87
Sanne I, Piliero P, Squires K, Thiry A, Schnittman S (2003) Results of a phase 2 clinical trial at 48 weeks (AI424–007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects.J Acquir Immune Defic Syndr 32: 18–29
Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, Cohen C, Poretz D, Markowitz M, Follansbee S et al. (1999) Ritonavir and saquinavir combination therapy for the treatment of HIV infection.AIDS 13: 213–224
Voigt E, Wickesberg A, Wasmuth JC, Gute P, Locher L, Salzberger B, Wohnmann A, Adam A, Weitner L, Rockstroh JK (2002) First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results.HIV Med 3: 277–282
Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D et al. (1998) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients.JAMA 279: 930–937
Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D et al. (2000) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.N Engl J Med; 341: 1865–1873
van Leth F, Hassink E, Phanuphak P, Miller S, Gazzard B, Cahn P, Wood R, Squires K, Katlama C, Santos B et al. (2003) Results of the 2NN study: a randomised comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine.10th Conference on Retroviruses and Opportunistic Infections 10–14 February 2003, Boston, Massachusetts, USA, Oral Abstract 176
Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J (2000) Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.AIDS 14: 807–812
Rachlis A, Becker S, Gill J, Dejesus E, Pierone G, Ruiz N, Aznar E (2001) Successful substitution of protease inhibitors with efavirenz in patients with undetectable viral loads.1st International AIDS Society Conference on HIV Pathogenesis and Treatment 8–11 July 2001, Buenos Aires, Argentina, Abstract 418
Martinez E, Garcia-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, Casamitjana R, Mallolas J, Gatell JM (2000) Impact of switching from human immunodeficiency virus type 1 protease inhibitor to efavirenz in successfully treated adults with lipodystrophy.Clin Infect Dis 31: 1266–1273
Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, Gel S, Bonjoch A, Fumaz CR, Johnston S et al. (2001) Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.J Acquir Immune Def Syndr 27: 229–236
Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, Johnson M, Gazzard B, Stone C, Athisegaran R et al. (2001) Simplification with abacavir-based triple nucleoside therapyversus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.AIDS 15: 1517–1526
Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E et al. (2002) A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.J Infect Dis 185: 1251–1260
Can A, Hudson J, Chuan J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA (2001) HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.AIDS 15: 1811–1822
Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M et al. (2001) Abacavir-lamuvidine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral naïve HIV-infected adults: a randomized equivalence trial.JAMA 285: 1155–1163
Martinez E, Mocroft A, Garcia-Viejo M, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A et al. (2001) Risk of lipodystrophy in HIV-1 infected patients treated with protease-inhibitors: a prospective cohort study.Lancet 357: 592–598
Carr A, Samaras K, Chisholm J Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance.Lancet 351: 1881–1883
Mallal SA, John M, Moore CB, James JR, McKinnon EJ (2000) Contribution of nucleoside ana-logue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.AIDS 14: 1309–1316
van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA (2001) Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included in the treatment of HIV-1 infection.AIDS 15: 847–855
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV (2002) MMWR Recomm Rep May 17: 1–55.http://www.hivatis.org57 The EACS Euroguidelines Group (2003) European guidelines for the clinical management and treatment of HIV infected adults in Europe.AIDS supplement to volume 17, 02 June 2003
Delta Coordinating Committee (1996) Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in infected individuals. individuals. Lancet 348: 283–291
Ruiz L, Carcelain G, Martinez-Picado J, Frost S, Marfil S, Paredes R, Romeu J, Ferrer E, MoralesLopetegi K, Autran B et al. (2001) HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 15: F19¡ªF27
Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar RL, Fox CH, Hallahan CW et al. (2001) Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci US A 98: 15161–15166
Hirschel B, Fagard C, Oxenius A, Gunthard H, Garcia F. (2002) A prospective trial of treatment interruptions in HIV infection. 9th Conference on Retroviruses and Opportunistic Infections 24–28 February 2002, Seattle, Washington, USA, Abstract 528-M
Staszewski S, Gallant J, Pozniak A, Suleiman JMAH, Dejesus E, Koenig E, Coleman S, Lu B, Cheng AK, Coakley DF (2002) Efficacy and safety of tenofovir disoproxil fumarate versus stavudine when used in combination with lamivudine and efavirenz in HIV-1 infected naïve patients to antiretroviral treatment: 48 weeks interim results. XIV“ International AIDS Conference 7–12 July 2002, Barcelona, Spain, Abstract Or17
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Conninck E, Conway B et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385–394
Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B (2002) Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16: 209–218
Katlama C, Dominguez S, Duvivier C, Delaugerre C, Peytavin G, Legrand M, Calvez V, Gourlain K, Costagliola D (2003) Long-term benefit of treatment interruption in salvage therapy (GIGHAART ARNS 097). 10th Conference on Retroviruses and Opportunistic Infections 10–14 February 2003, Boston, Massachusetts, USA, Oral Abstract 68
Lalezari JP, Henry K, O’Hearn M, Lefebvre E, Monaner J, Piliero P, Walmsley S, Chung J, Fang L, Delehanty J et al. (2002) Enfuvirtide (T-20) in combination with an optimized background (OB) regimen versus OB alone: Week 24 response among categories of treatment experience and baseline (BL) HIV antiretroviral (AVR) resistance. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy 27–30 September 2002, San Diego, California, USA, Abstract H-1074
Ho DD (1998) Toward HIV eradication or remission: the tasks ahead. Science 280: 1866–1867
Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B (1998) Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351: 1682–1686
Kovacs JA, Vogel S, Albert TM, Falloon J, Davey RT Jr, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M et al. (1996) Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 335: 1350–1356
Hengge UR, Goos M, Esser S, Exner V, Dotterer, Wiehler H, Borchard C, Muller K, Beckmann A, Eppner MT et al. (1998) Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 12: F225¡ªF234
Losso MH, Belloso WH, Emery S, Benetucci JA, Cahn PE, Lasala MC, Lopardo G, Salomon H, Saracco M, Nelson E et al. (2000) A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >_350 cells/mm3. J Infect Dis 181: 1614–1621
Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG,Dewar RL, Sahner DK et al. (2000) Immunologic and virologie effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 284: 183–189
Abrams DI, Bebchuk JD, Denning ET, Davey RT, Fox L, Lane HC, Sampson J, Verheggen R, Zeh D, Markowitz NP (2002) Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of >_300 cells/mm3. J Acquir Immune Defic Syndr 29: 221–231
Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Oksenhendler E, Weiss L, Gastaut JA et al. (2003) Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 17: 343–351
Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, Zagury L, Calvez V, Autran B, Costagliola D (2002) Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study-ANRS 082. AIDS 16: 2027–2034
Frumkin L (1997) Role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of patients with HIV infection. Curr Opin Hematol 4: 200–206
Hardy GA, Imami N, Gotch FM (2002) Improving HIV-specific immune responses in HIV-infected patients. J HIV Ther 7: 40–45
Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Montefiori DC, O’Connor DH, Davis BT, Lee PK et al. (2002) HIV-1 superinfection despite broad CD8+ T -cell responses containing replication of the primary virus. Nature 420: 434–439
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Basel AG
About this chapter
Cite this chapter
Konopnicki, D., Clumeck, N. (2004). A perspective of the history of HAART. In: De Clercq, E.D.A., Vandamme, AM.I. (eds) Combination Therapy of AIDS. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7869-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7869-2_2
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9604-7
Online ISBN: 978-3-0348-7869-2
eBook Packages: Springer Book Archive